al2846
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2016 (NCT02779699)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- al2846
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06860971 | Phase 3 | Apr 18, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05745363 | Phase 1/Phase 2 (Phase 2) | Feb 24, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05815862 | Phase 2 | Feb 15, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06116240 | Phase 1 | Sep 2, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05011019 | Phase 1/Phase 2 (Phase 2) | Sep 7, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04325776 | Phase 2 | Apr 30, 2020 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04337879 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2020 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT02779699 | Phase 1 | May 1, 2016 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 8 | 8 | 3 | 2016 |
1 organizations
Page 1 / 1